- +852 4750 3485
- info@mycancerinfo.org
Triple-negative breast cancer (TNBC) remains one of the most aggressive subtypes of breast cancer, with limited targeted treatment options. While PARP inhibitors (PARPi) have shown clinical benefit in selected patients, resistance—either intrinsic or acquired—remains a major challenge.
Recent research suggests that targeting the oncogene MYC using a novel inhibitor known as Omomyc may enhance the effectiveness of PARP inhibitors, offering a potential new therapeutic strategy.
MYC is a transcription factor that regulates genes involved in:
Dysregulation of MYC is observed in a large proportion of human cancers and is associated with tumour progression, metastasis, and treatment resistance.
Importantly, MYC also plays a dual role in the DNA damage response (DDR):
This balance enables cancer cells to tolerate high levels of DNA damage while maintaining growth.
PARP inhibitors, such as olaparib and talazoparib, are designed to target cancers with deficiencies in DNA repair pathways, particularly those with BRCA1/2 mutations.
However, their effectiveness is limited by:
Overcoming PARPi resistance remains a key unmet need in oncology.
Omomyc is a first-in-class direct MYC inhibitor, developed after decades of research targeting MYC—a protein long considered “undruggable.”
Key characteristics:
Recent preclinical studies show that MYC inhibition with Omomyc:
Together, this creates a synthetic vulnerability, where cancer cells become more dependent on PARP pathways for survival.
The effectiveness of cancer treatment varies among each patient.
The combination of Omomyc and PARP inhibitors demonstrated significantly enhanced tumour suppression compared to either treatment alone.
The combination remained effective even in models with PARP inhibitor resistance, suggesting a potential strategy to overcome treatment failure.
High MYC activity was associated with poor response to PARP inhibitors, indicating that MYC may serve as a predictive biomarker for treatment response.
This research highlights several important developments in cancer care:
MYC has long been considered difficult to target. The development of Omomyc represents a significant breakthrough in oncology.
Combining targeted therapies may improve outcomes by addressing multiple survival pathways simultaneously.
Identifying biomarkers such as MYC activity may help guide treatment selection and improve patient stratification.
While promising, this approach is not yet part of standard clinical practice.
The combination of MYC inhibition using Omomyc with PARP inhibitors represents a promising strategy to enhance treatment response in breast cancer, particularly in resistant disease.
By targeting both DNA repair mechanisms and oncogenic signalling pathways, this approach may offer a more effective and durable therapeutic option in the future.
More broadly, it reflects a growing trend in oncology: combining targeted therapies to exploit cancer-specific vulnerabilities and improve treatment precision.
Precision medicine provides patients with clearer and more personalized treatment guidelines
Learn how precision medicine can help with your cancer treatment
The effectiveness of cancer treatment varies among each patient.
